News

Hosted on MSN13d
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...
MPR8d
High Dose Aflibercept Gets Priority Review for Retinal Vein Occlusion and Monthly Dosing
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...
Ophthalmology Times2d
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR
The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...
Seeking Alpha13d
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly ...
EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...
Ophthalmology Times13d
Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...
Nasdaq13d
Regeneron's SLBA For EYLEA HD Injection 8 Mg Gets Acceptance From FDA For Priority Review
Inc. (REGN), Thursday announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg ...
The Pharma Letter12d
Eylea HD injection 8mg sBLA accepted for FDA Priority Review
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...
Pharm Exec13d
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
The FDA has granted Priority Review status to Regeneron’s and Bayer’s supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The application seeks to expand use ...
Nasdaq13d
Regeneron Announces FDA Acceptance of Priority Review for EYLEA HD® Supplemental Application for Retinal Vein Occlusion Treatment
Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which ...